卡度尼利单抗致肾上腺皮质功能减退1例分析

doi:10.19803/j.1672-8629.20240554

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (1): 109-112.
DOI: 10.19803/j.1672-8629.20240554

卡度尼利单抗致肾上腺皮质功能减退1例分析

刘楠楠^1,2, 席雅琳², 陈喆^1,*

¹国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院药剂科,北京 100021;
²大连市中心医院药剂科,辽宁大连 116400

收稿日期:2024-08-02 出版日期:2025-01-15 发布日期:2025-01-22
通讯作者: ^*陈喆,女,硕士,副主任药师,肿瘤临床药学。E-mail: gigichen79@126.com
作者简介:刘楠楠,女,硕士,主管药师,肿瘤临床药学。

One Case of Adrenocortical Insufficiency Caused by Cadonilimab

LIU Nannan^1,2, XI Yalin², CHEN Zhe^1,*

¹Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
²Department of Pharmacy, Dalian Municipal Central Hospital, Dalian Liaoning 116400, China

Received:2024-08-02 Online:2025-01-15 Published:2025-01-22

摘要/Abstract

摘要： 目的分析卡度尼利单抗致肾上腺皮质功能减退的临床特点、危险因素及治疗等内容,为临床用药提供参考。方法对1例卡度尼利单抗致3级肾上腺皮质功能减退的病例进行分析,并对相关文献进行归纳总结。结果患者使用卡度尼利单抗后出现的乏力、恶心、低血钠等症状很可能为免疫相关性肾上腺皮质功能减退,患者停用卡度尼利单抗,并加用口服激素治疗后,不适症状消失,且依从性良好。结论卡度尼利单抗治疗过程中需关注患者的临床症状,如出现乏力、恶心、低钠血症等情况,应警惕药物相关肾上腺皮质功能减退的可能性,及时采取应对措施,对改善患者预后具有重要意义。

关键词: 卡度尼利单抗, 免疫检查点抑制剂, 免疫相关不良事件, 肾上腺皮质功能减退, 垂体炎, 临床药师

Abstract: Objective To analyze the clinical characteristics, risk factors, and treatment of adrenal insufficiency caused by cadonilimab and to explore the role of clinical pharmacists in the management of immune-related adverse events. Methods A case of 3rd grade adrenal insufficiency caused by cadonilimab was analyzed, and the related literature was summarized. Clinical pharmacists gave advice on management of adverse reactions, pharmaceutical care and medications. Results The fatigue, nausea, and hyponatremia experienced by the patient after receiving cadonilimab were likely attributed to immune-related adrenocortical insufficiency. After discontinuation of cadonilimab and start of oral steroid therapy, the patient had no more discomfort with good compliance. Conclusion During the treatment with cadonilimab, it is important to monitor the patient's clinical symptoms, such as fatigue, nausea, hyponatremia, which may indicate the chance of drug-related adrenal insufficiency. Quick countermeasures can be crucial to improving the patient's prognosis.

Key words: Cadonilimab, Immune Checkpoint Inhibitors (ICIs), Immune-Related Adverse Event, Adrenal Insufficiency, Hypophysitis, Clinical Pharmacists

中图分类号:

刘楠楠, 席雅琳, 陈喆. 卡度尼利单抗致肾上腺皮质功能减退1例分析[J]. 中国药物警戒, 2025, 22(1): 109-112.

LIU Nannan, XI Yalin, CHEN Zhe. One Case of Adrenocortical Insufficiency Caused by Cadonilimab[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 109-112.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240554

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I1/109

参考文献

[1] KEAM SJ.Cadonilimab: First Approval[J]. Drugs, 2022, 82(12): 1333-1339.
[2] XU Q, XU T.A Case of Pituitary Crisis Caused By Cadonilimab Treatment of Advanced Gastric Cancer[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2024, 33(1): 116-120.
[3] FAJE AT, SULLIVAN R, LAWRENCE D, et al.Ipilimumab-Induced Hypophysitis: a Detailed Longitudinal Analysis in a Large Cohort of Patients with Metastatic Melanoma[J]. J Clin Endocrinol Metab, 2014, 99(11): 4078-4085.
[4] ASCIERTO PA, DEL VECCHIO M, ROBERT C, et al.Ipilimumab 10 mg·kg^-1 vs Ipilimumab 3 mg·kg^-1 in Patients with Unresectable or Metastatic Melanoma: a Randomised, Double-Blind, Multicentre, Phase 3 Trial[J]. Lancet Oncol, 2017, 18(5): 611-622.
[5] CHANG LS, BARROSO-SOUSA R, TOLANEY SM, et al.Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints[J]. Endocr Rev, 2019, 40(1): 17-65.
[6] Immune-Endocrinology Group, Chinese Society of Endocrinology, Chinese ledical Association. Chinese Expert Consensus on the Immune Checkpoint Inhibitors-Induced Endocrine Immune-Related Adverse Events(2020)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2021, 37(1): 1-16.
[7] WRIGHT JJ, POWERS AC, JOHNSON DB.Endocrine Toxicities of Immune Checkpoint Inhibitors[J]. Nat Rev Endocrinol, 2021, 17(7): 389-399.
[8] SALABEI JK, UPADHYAY D, PADAM SA.Induction of Hypopituitarism Following Ipilimumab/Nivolumab Therapy Followed by Radiation in the Treatment of Metastatic Scalp Melanoma[J]. HCA Healthc J Med, 2021, 2(5): 339-343.
[9] Obesity Group, Chinese Society of Endocrinology, Chinese Medical Association. Expert Consensus on the Management of Glucocorticoids During the Perioperative Period for Patients with Adrenal Insufficiency[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2022, 38(1): 1-6.
[10] MIHIC-PROBST D, REINEHR M, DETTWILER S, et al.The Role of Macrophages Type 2 and T-Regs in Immune Checkpoint Inhibitor Related Adverse Events[J]. Immunobiology, 2020, 225(5): 152009.
[11] CATUREGLI P, DI DALMAZI G, LOMBARDI M, et al.Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade[J]. Am J Pathol, 2016, 186(12): 3225-3235.
[12] Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Immune Checkpoint Inhibitor-Related Toxicity Management Guidelines[中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南][M]. Beijing: People's Medical Publishing House, 2023.
[13] SCHNEIDER BJ, NAIDOO J, SANTOMASSO BD, et al.Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update[J]. J Clin Oncol, 2021, 39(36): 4073-4126.
[14] U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version5.0[EB/OL]. (2017-11-27) [ 2024-06-13]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
[15] Chinese Society of Endocrinology, China Endocrinology and Metabolism Specialist Alliance. Principles for Clinical Application of Glucocorticoids(2023 Edition)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2023, 39(4): 289-296.
[16] National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities(Version 1.2024) [EB/OL]. (2023-12-07) [2024-06-13]. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1486.
[17] HAANEN J, OBEID M, SPAIN L, et al.Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up[J]. Ann Oncol, 2022, 33(12): 1217-1238.

卡度尼利单抗致肾上腺皮质功能减退1例分析

One Case of Adrenocortical Insufficiency Caused by Cadonilimab

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙熙木, 周涵, 李雁铭, 郭鹏, 聂晓璐. 基于美国FAERS数据库的免疫检查点抑制剂相关血小板减少症信号挖掘与分析[J]. 中国药物警戒, 2025, 22(1): 23-28.
[2]	张彩霞, 周易, 谭璐, 陈文明, 柳阳, 游禹. 1例脓毒血症继发肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2024, 21(9): 1064-1067.
[3]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[4]	林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳. 1例伊立替康致结肠癌患者急性肝损伤的药学监护[J]. 中国药物警戒, 2024, 21(6): 693-696.
[5]	张健, 张伶俐, 李歆. 424例替雷利珠单抗致免疫相关不良事件分析[J]. 中国药物警戒, 2024, 21(4): 435-439.
[6]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[7]	刘琦, 张玉凤, 罗皓, 李歆. 106例安罗替尼临床应用的合理性与安全性分析[J]. 中国药物警戒, 2024, 21(3): 329-334.
[8]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[9]	刘鑫, 王国俊. 2例糖皮质激素药物致高血压的药学监护[J]. 中国药物警戒, 2024, 21(11): 1303-1305.
[10]	汪滢, 黄珊, 沈钦勇, 连霞, 常颖, 江彦, 林兵, 黄爱文. 79例替雷利珠单抗相关不良反应分析[J]. 中国药物警戒, 2024, 21(10): 1148-1153.
[11]	张立, 汪余嘉, 张玲玲, 陈家鑫, 林敏华, 林小惠, 聂雪坤. 真实世界免疫检查点抑制剂相关不良反应监测数据分析[J]. 中国药物警戒, 2023, 20(9): 1035-1038.
[12]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[13]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[14]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[15]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.